The Chao Family Comprehensive Cancer Center is pleased to announce the launch of the Women’s Cancer Cure ConneXion (WCCC). Following the Colon Cancer Disease Oriented Team (DOT), the WCCC is the second DOT activated by the Cancer Center. Importantly, the Women’s DOT is comprised of physician scientists, clinicians, and translational researchers who have an expertise in breast and gynecologic cancers. This is a highly innovative concept that serves to enrich the preventative and therapeutic strategies for women’s cancers under one umbrella.
We are excited to continue to bring together collaborative efforts and the opportunity to advance the treatment and prevention of Women’s Cancer through Cure ConneXion (X=eradicate cancer). The WCCC-DOT will engage investigators who have an interest in translational science, comparative effectiveness research in surgery, health care disparities and drug discovery in breast, ovarian, endometrial, cervical and vulvar cancers. I invite you to read more about the Women’s Cancer Cure ConneXion DOT’s purpose, leadership and membership here.
If you are interested in joining this exciting collaborative opportunity, please contact one of the following team leaders below:
- Dr. Krishnansu Tewari, associate professor, Department of Obstetrics & Gynecology, Director of Research-Gynecologic Oncology (firstname.lastname@example.org)
- Dr. Lydia Su, Professor, Department of Radiologic Sciences, Director of Tu & Yuen Center for Functional Onco-Imaging (email@example.com)
You may also contact the Women’s Cancer Cure ConneXion DOT administrative leader:
Jacquie Tidball (firstname.lastname@example.org).
Frank L. Meyskens, Jr., M.D., F.A.C.P.
The Daniel G. Aldrich, Jr. Endowed Chair
Professor of Medicine, Biological Chemistry
and Public Health
Director, Chao Family / NCI Designated
Comprehensive Cancer Center
University of California, Irvine
Tel: (714) 456-6310
Fax: (714) 456-2240